Christopher Martell is Director at Candel Therapeutics, Inc. (CADL). They have made 2 open-market trades across 1 company since 2021, most recently 2025-06-25.
CIK 0001873465
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $1.1M since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CADL | 111,349 | $911K |
Shares reported on the most recent Form 4, priced at the 2025-06-26 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.